Indication
Lupus Nephritis
64 clinical trials
76 products
6 drugs
Clinical trial
A Two-year, Phase III Randomized, Double-blind, Parallel-group, Placebo-controlled Trial to Evaluate the Safety, Efficacy, and Tolerability of 300 mg s.c. Secukinumab Versus Placebo, in Combination With SoC Therapy, in Patients With Active Lupus NephritisStatus: Terminated, Estimated PCD: 2023-09-13
Product
secukinumabClinical trial
Evaluating the Safety of Myfortic (Mycophenolate Sodium) in Patients With Lupus Nephritis: a 12 Month, Single-arm, Observational Study in Taiwan PopulationStatus: Active (not recruiting), Estimated PCD: 2024-08-30
Product
MyforticProduct
povetaciceptClinical trial
An Open-Label, Multiple-Ascending Dose Study to Assess the Safety, Efficacy, Pharmacokinetics, and Pharmacodynamics of Different Dose Levels of Povetacicept in Subjects With Autoantibody-Associated Glomerular Diseases (RUBY-3)Status: Recruiting, Estimated PCD: 2026-01-01
Product
SecukinumabClinical trial
A Three-year, Open-label Extension Study of Subcutaneous Secukinumab to Evaluate the Long-term Efficacy, Safety and Tolerability in Patients With Active Lupus NephritisStatus: Terminated, Estimated PCD: 2023-08-23
Product
AB-101Clinical trial
A Phase 1 Study to Evaluate the Efficacy and Safety of AB-101, an Allogeneic Cord Blood- Derived NK-Cell Therapy in Combination With B-Cell Depleting mAb in Patients Who Failed Treatment for Class III or IV Lupus NephritisStatus: Recruiting, Estimated PCD: 2026-10-01
Product
FludarabineProduct
CyclophosphamideProduct
RituximabClinical trial
A Prospective Observational Registry of Patients Treated With LUPKYNIS™ (Voclosporin) in the USStatus: Recruiting, Estimated PCD: 2026-11-15
Product
LUPKYNISClinical trial
A Multicenter, Randomized, Double-Blinded, Placebo-Controlled, Proof-of-Concept Study to Evaluate the Efficacy and Safety of Efgartigimod in Chinese Patients With Lupus NephritisStatus: Recruiting, Estimated PCD: 2024-08-01
Clinical trial
A Multicenter Phase I/II Clinical Trial to Evaluate the Safety, Tolerability, and Efficacy of RY_SW01cell Injection Therapy in Active Lupus NephritisStatus: Recruiting, Estimated PCD: 2025-12-31
Product
EfgartigimodProduct
RY_SW01Product
Basic treatmentProduct
voclosporinClinical trial
An Open-Label Extension Study to Assess the Long-Term Safety and Efficacy of Voclosporin in Adolescent Subjects With Lupus NephritisStatus: Not yet recruiting, Estimated PCD: 2026-06-01
Product
ZanubrutinibClinical trial
A Phase 2, Multicenter, Randomized, Double Blind, Placebo Controlled Study to Evaluate the Safety and Efficacy of Zanubrutinib in Patients With Active Proliferative Lupus NephritisStatus: Active (not recruiting), Estimated PCD: 2024-02-26
Product
PlaceboProduct
Mesenchymal stem cellsClinical trial
Phase II, Double-Blind, Placebo-Controlled Clinical Trial to Evaluate Safety and Efficacy of Mesenchymal Stem Cells (MSV-allo) in the Treatment of Lupus NephritisStatus: Recruiting, Estimated PCD: 2025-07-01
Product
YTB323Clinical trial
An Open-label, Multi-center, Phase 1/2 Study to Assess Safety, Efficacy and Cellular Kinetics of YTB323 in Participants With Severe, Refractory Systemic Lupus ErythematosusStatus: Recruiting, Estimated PCD: 2026-10-09
Product
GuselkumabClinical trial
A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Study of Guselkumab in Subjects With Active Lupus NephritisStatus: Terminated, Estimated PCD: 2023-02-01
Product
Standard-of-care treatmentClinical trial
A Phase 1/2 Open-label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of IMPT-514 in Participants With Active, Refractory Lupus Nephritis and Systemic Lupus ErythematosusStatus: Recruiting, Estimated PCD: 2027-02-01
Product
IMPT-514Product
ObinutuzumabClinical trial
A Phase II, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Obinutuzumab in Adolescent Patients With Active Class III or IV Lupus Nephritis, Including an Evaluation of Open Label Safety and PK in a Cohort of Pediatric Patients (Aged 5 to < 12)Status: Recruiting, Estimated PCD: 2026-03-31
Product
Mycophenolate MofetilProduct
Acetaminophen/paracetamolProduct
MethylprednisoloneProduct
DiphenhydramineProduct
PrednisoneClinical trial
A Multicentre Randomized Double-Blind Placebo Controlled Phase 3 Study to Evaluate the Efficacy and Safety of Anifrolumab in Adult Patients With Active Proliferative Lupus NephritisStatus: Recruiting, Estimated PCD: 2026-09-30
Product
AnifrolumabClinical trial
A Phase 1b/2 Study of KZR-616 in Patients With Systemic Lupus Erythematosus With and Without Nephritis (MISSION)Status: Completed, Estimated PCD: 2022-08-04
Product
KZR-616Product
ADI-001Clinical trial
A Phase 1 Study of ADI-001 Anti-CD20 CAR-engineered Allogeneic Gamma-Delta (γδ) T Cells in Adults With Lupus NephritisStatus: Not yet recruiting, Estimated PCD: 2026-12-01
Clinical trial
A Phase 1b, Open-Label, Multicenter Study to Evaluate the Safety and Efficacy of TAK-007, an Allogeneic Anti-CD19 Chimeric Antigen Receptor Natural Killer Cell (CD19 CAR-NK) Therapy, in Adult Subjects With Refractory Lupus NephritisStatus: Not yet recruiting, Estimated PCD: 2029-04-23
Product
Chemotherapy AgentsProduct
TAK-007Product
Voclosporin（QL1074）Clinical trial
A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study Comparing the Efficacy and Safety of QLG1074 With Placebo in Achieving Renal Remission in Subjects With Active Lupus NephritisStatus: Recruiting, Estimated PCD: 2027-06-01
Clinical trial
A Phase 1b Multiple Ascending-dose Study of EQ001 in Subjects With Systemic Lupus Erythematosus With or Without Active Proliferative Lupus NephritisStatus: Completed, Estimated PCD: 2023-11-16
Product
ItolizumabProduct
ALXN2050Clinical trial
A Phase 2, Randomized, Double-blind, Placebo-controlled, Dose-finding Study to Evaluate the Efficacy and Safety of ALXN2050 in Adult Participants With Proliferative Lupus Nephritis (LN) or Immunoglobulin A Nephropathy (IgAN)Status: Recruiting, Estimated PCD: 2026-06-30
Product
KYV-101Clinical trial
A Phase 1/2, Open-Label, Multicenter Study of KYV-101, an Autologous Fully-Human Anti-CD19 Chimeric Antigen Receptor T-Cell (CD19 CAR T) Therapy, in Subjects With Refractory Lupus NephritisStatus: Recruiting, Estimated PCD: 2028-10-01
Clinical trial
A Phase 1/2, Open-Label, Multicenter Study of KYV-101, an Autologous Fully-Human Anti-CD19 Chimeric Antigen Receptor T-Cell (CD19 CAR T) Therapy, in Subjects With Refractory Lupus Nephritis (KYSA-1)Status: Recruiting, Estimated PCD: 2025-08-01
Clinical trial
A Single-Arm, Phase 1b, Open-Label Study to Assess the Safety, Tolerability, and Pharmacodynamics of Repeat-Doses of Subcutaneous ANX009 With Standard of Care Therapy in Adult Participants With Lupus NephritisStatus: Recruiting, Estimated PCD: 2023-06-30
Clinical trial
A Phase 2, Randomized, Double-blind, Placebo-controlled Evaluation of the Safety and Efficacy of BMS-986165 With Background Treatment in Subjects With Lupus NephritisStatus: Terminated, Estimated PCD: 2020-10-29
Clinical trial
A Randomized, Placebo-controlled, Patient and Investigator Blinded, Study Investigating the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of Multiple Doses of CFZ533 in Patients With Moderately Active Proliferative Lupus NephritisStatus: Completed, Estimated PCD: 2023-06-29
Product
BMS-986165Product
CFZ533Product
ANX009Product
VoclosporinClinical trial
A Randomized, Controlled, Double-blind, Continuation Study Comparing the Long-term Safety and Efficacy of Voclosporin (23.7 mg Twice Daily) With Placebo in Subjects With Lupus NephritisStatus: Completed, Estimated PCD: 2021-10-07
Product
APL-2Clinical trial
A Phase 2 Study to Evaluate the Safety and Biologic Activity of APL- 2 in Patients With IgA Nephropathy, Lupus Nephritis, Primary Membranous Nephropathy, or C3 Glomerulopathy (C3 Glomerulonephritis and Dense Deposit Disease)Status: Active (not recruiting), Estimated PCD: 2020-04-16
Clinical trial
A Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study to Evaluate the Safety and Efficacy of Obinutuzumab in Patients With ISN/RPS 2003 Class III or IV Lupus NephritisStatus: Completed, Estimated PCD: 2019-01-15
Clinical trial
An Adaptive, Randomized, Double-blind, Dose Exploration, Parallel Group, Placebo Controlled, Multicenter Phase 2 Trial to Evaluate the Efficacy, Safety and Tolerability of LNP023 in Combination With Standard-of-care With and Without Oral Corticosteroids in Patients With Active Lupus Nephritis Class III-IV, +/- VStatus: Recruiting, Estimated PCD: 2024-10-24
Product
IptacopanClinical trial
A Randomized, Controlled Double-blind Study Comparing the Efficacy and Safety of Voclosporin (23.7 mg Twice Daily) With Placebo in Achieving Renal Response in Subjects With Active Lupus NephritisStatus: Completed, Estimated PCD: 2019-09-24
Product
Placebo + standard of careProduct
TelitaciceptClinical trial
A Phase Ⅱ, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Telitacicept in Lupus NephritisStatus: Recruiting, Estimated PCD: 2024-12-01
Clinical trial
A Double-Blind, Placebo-Controlled, Dose Escalation Study to Assess the Efficacy, Safety and Pharmacokinetics of Voclosporin in Adolescents With Lupus NephritisStatus: Recruiting, Estimated PCD: 2024-12-01
Clinical trial
Evaluation of the Safety and Efficacy of FKC288 in Participants With Autoimmune Kidney Diseases: A Single-center Exploratory Clinical StudyStatus: Recruiting, Estimated PCD: 2026-12-31
Product
FKC288Clinical trial
An Open Label Phase 1b Study of Felzartamab in Lupus NephritisStatus: Recruiting, Estimated PCD: 2025-05-01
Product
FelzartamabClinical trial
Assessment of Safety and Efficacy of Sodium Glucose Co-transporter 2 Inhibitors Among Lupus Nephritis PatientsStatus: Not yet recruiting, Estimated PCD: 2024-12-01
Product
DapagliflozinClinical trial
A Phase 2 Open-label Trial Evaluating the Efficacy and Safety of Daratumumab in Treatment of Patients With Active Lupus NephritisStatus: Recruiting, Estimated PCD: 2026-07-01
Product
DaratumumabClinical trial
Refractory ANCA Associated Vasculitis and Lupus Nephritis Treated With BCMA-targeting CAR-T CellsStatus: Recruiting, Estimated PCD: 2026-02-01
Product
PRG-1801Clinical trial
CARTIMMUNE: A Single-Center Study of Patients With Autoimmune Diseases Receiving an Autologous Fully-Human Anti-CD19 Chimeric Antigen Receptor T-Cell (KYV 101)Status: Not yet recruiting, Estimated PCD: 2028-06-01
Clinical trial
A Randomized Controlled Trial on SGLT2 Inhibitor in Lupus Nephritis Patients With Chronic Kidney DiseaseStatus: Not yet recruiting, Estimated PCD: 2026-11-30
Product
Standard maintenance therapyClinical trial
A Phase 2a Randomized Placebo-Controlled Double-Blind Multicenter Trial of VIB4920 for Active Lupus Nephritis (ITN091AI)Status: Recruiting, Estimated PCD: 2026-08-01
Product
VIB4920Clinical trial
Efficacy & Safety of Pharmacokinetically-Driven Dosing of Mycophenolate Mofetil for the Treatment of Pediatric Proliferative Lupus Nephritis- A Double-Blind Placebo Controlled Clinical TrialStatus: Recruiting, Estimated PCD: 2025-07-01
Clinical trial
Effectiveness of Mycophenolate Mofetil Combined With Tacrolimus for Steroid Tapering in Systemic Lupus Erythematosus: A Prospective, Random Control, Open-label, Single Center Clinical TrialStatus: Recruiting, Estimated PCD: 2025-07-31
Product
TacrolimusProduct
GlucocorticoidClinical trial
A Randomized Open-label Study to Evaluate the Efficacy and Safety of Tacrolimus and Corticosteroids in Comparison With Mycophenolate Mofetil and Corticosteroids in Subjects With Class III/IV±V Lupus NephritisStatus: Active (not recruiting), Estimated PCD: 2025-01-31
Product
Mycophenolate mofetilClinical trial
A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study To Evaluate The Efficacy And Safety Of Obinutuzumab In Patients With ISN/RPS 2003 Class III Or IV Lupus Nephritis (REGENCY)Status: Active (not recruiting), Estimated PCD: 2024-08-16
Drug
R-CHOPDrug
VarlilumabProduct
AcetaminophenClinical trial
The Effect of Curcumin on the Clinical Outcome of Pediatric Patients With Active Lupus NephritisStatus: Recruiting, Estimated PCD: 2023-10-01
Product
CurcuminClinical trial
A Phase 1/2, Open-label Study to Evaluate the Safety and Efficacy of Autologous CD19-specific Chimeric Antigen Receptor T Cells (CABA-201) in Subjects With Active Systemic Lupus ErythematosusStatus: Recruiting, Estimated PCD: 2027-12-01
Product
CABA-201Clinical trial
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study Evaluating the Efficacy and Safety of Daxdilimab in Adult Participants With Active Proliferative Lupus NephritisStatus: Terminated, Estimated PCD: 2024-01-04
Product
DaxdilimabClinical trial
A Phase 2b, Randomized, Controlled Double-blind, Multicenter Study Comparing the Efficacy and Safety of Zetomipzomib (KZR-616) 30 mg or 60 mg With Placebo in Patients With Active Lupus NephritisStatus: Recruiting, Estimated PCD: 2026-05-01
Product
zetomipzomibDrug
placeboClinical trial
A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of Nipocalimab in Adult Participants With Active Lupus NephritisStatus: Not yet recruiting, Estimated PCD: 2028-02-28
Product
NipocalimabClinical trial
CNCT19 Cell Injection for Refractory Systemic Lupus ErythematosusStatus: , Estimated PCD: 2024-05-30
Product
CNCT19Clinical trial
Phase 1b/2a Trial of Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) From an HLA-partially Matched Related or Unrelated Donor After TCRαβ+ T-cell/CD19+ B-cell Depletion for Patients Who Will Receive a Kidney Transplant (KT) From the Same HSCT/KT DonorStatus: Recruiting, Estimated PCD: 2032-10-01
Drug
fludarabineProduct
ATGDrug
MelphalanClinical trial
Clinical Trial of Belimumab Combined With Multi-target Induction Therapy in Adult Patients With Severe Lupus NephritisStatus: Recruiting, Estimated PCD: 2024-03-31
Product
BelimumabProduct
Immunosuppressive AgentsClinical trial
Pharmacokinetically-driven Dosing of Mycophenolate Mofetil for the Treatment of Pediatric Proliferative Lupus NephritisStatus: Withdrawn, Estimated PCD: 2024-01-01
Clinical trial
A Phase 1 Study to Evaluate the Safety and Preliminary Efficacy of ATA3219, Allogeneic Anti-CD19 Chimeric Antigen Receptor T-cell (CAR T) Therapy, in Subjects With Lupus NephritisStatus: Not yet recruiting, Estimated PCD: 2027-10-01
Product
ATA3219Clinical trial
Induction Therapy for Lupus Nephritis With no Added Oral Steroids: An Open Label Randomised Multicentre Controlled Trial Comparing Oral Corticosteroids Plus Mycophenolate Mofetil (MMF) Versus Obinutuzumab and MMFStatus: Recruiting, Estimated PCD: 2031-12-01
Clinical trial
Comparing Efficacy and Safety of Mescaline Sodium Enteric-coated Tablets vs Morte-mescaline in the Treatment of Adult Lupus Nephritis: A Prospective, Multicenter,Real-world StudyStatus: Not yet recruiting, Estimated PCD: 2025-07-01
Product
Mescaline sodiumProduct
Morte-mescalineClinical trial
Study of the Cardio Renal Effects of SGLT2 Inhibitors Among Diabetic and Non-diabetic Lupus Nephritis PatientsStatus: Active (not recruiting), Estimated PCD: 2023-10-01
Product
dapagliflozinClinical trial
SGLT2 Inhibitors Between Reno Protective Effects and Impact on Bone and Mineral Disease Among Diabetic and Non- Diabetic Lupus Nephritis PatientsStatus: Active (not recruiting), Estimated PCD: 2023-10-08
Product
GlucocorticoidsClinical trial
Dose-response and Efficacy of Umbilical Cord-derived Mesenchymal Stromal Cells in Renal Systemic Lupus ErythematosusStatus: Recruiting, Estimated PCD: 2024-12-01
Product
MSC treatmentProduct
Standard of CareClinical trial
A Randomized, Double-blind, Parallel Group, Placebo-controlled, Multicenter Phase 3 Trial to Evaluate Efficacy, Safety and Tolerability of Ianalumab on Top of Standard-of-care Therapy in Participants With Active Lupus Nephritis (SIRIUS-LN).Status: Recruiting, Estimated PCD: 2027-03-01
Product
IanalumabClinical trial
A Phase III, Randomized, Open, Parallel-controlled, Multi-center Study to Compare the Efficacy and Safety of Tacrolimus Capsules and Cyclophosphamide Injection in Treatment of Lupus NephritisStatus: Completed, Estimated PCD: 2018-09-10
Clinical trial
Safety and Efficacy of Umbilical Cord Mesenchymal Stem Cell Transfusion for the Treatment of Refractory Lupus NephritisStatus: Not yet recruiting, Estimated PCD: 2026-10-01